CHICAGO--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced data from two large, Phase III clinical trials that assessed the efficacy and safety profile at 24 weeks in rheumatoid arthritis (RA) patients who received ACTEMRA® (tocilizumab) as a monotherapy as well as those who received ACTEMRA plus a disease-modifying antirheumatic drug (DMARD), including methotrexate (MTX). These data will be presented as oral and poster presentations at the 2011 American College of Rheumatology (ACR) Annual Scientific Meeting in Chicago, November 5-9.
